109 related articles for article (PubMed ID: 7982624)
1. Free radical formation by ansamycin benzoquinone in human breast tumor cells: implications for cytotoxicity and resistance.
Benchekroun NM; Myers CE; Sinha BK
Free Radic Biol Med; 1994 Sep; 17(3):191-200. PubMed ID: 7982624
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of resistance to ansamycin antibiotics in human breast cancer cell lines.
Benchekroun MN; Schneider E; Safa AR; Townsend AJ; Sinha BK
Mol Pharmacol; 1994 Oct; 46(4):677-84. PubMed ID: 7969046
[TBL] [Abstract][Full Text] [Related]
3. Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance.
Sinha BK; Mimnaugh EG; Rajagopalan S; Myers CE
Cancer Res; 1989 Jul; 49(14):3844-8. PubMed ID: 2544260
[TBL] [Abstract][Full Text] [Related]
4. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin.
Schulte TW; Neckers LM
Cancer Chemother Pharmacol; 1998; 42(4):273-9. PubMed ID: 9744771
[TBL] [Abstract][Full Text] [Related]
5. Biochemical and pharmacological characterization of MCF-7 drug-sensitive and AdrR multidrug-resistant human breast tumor xenografts in athymic nude mice.
Mimnaugh EG; Fairchild CR; Fruehauf JP; Sinha BK
Biochem Pharmacol; 1991 Jul; 42(2):391-402. PubMed ID: 1677569
[TBL] [Abstract][Full Text] [Related]
6. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells.
Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y
Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866
[TBL] [Abstract][Full Text] [Related]
7. Combined effect of epirubicin and lymphokine-activated killer cells on the resistant human breast cancer cells.
Ozkan A; Ayhan A; Fiskin K
Cell Biol Toxicol; 2004 Sep; 20(5):261-71. PubMed ID: 15685929
[TBL] [Abstract][Full Text] [Related]
8. Alpha-fetoprotein-mediated targeting--a new strategy to overcome multidrug resistance of tumour cells in vitro.
Moskaleva EYu ; Posypanova GA; Shmyrev II; Rodina AV; Muizhnek EL; Severin ES; Katukov VYu ; Luzhkov YM; Severin SE
Cell Biol Int; 1997 Dec; 21(12):793-9. PubMed ID: 9812343
[TBL] [Abstract][Full Text] [Related]
9. Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression.
Chao CC
FEBS Lett; 1995 Oct; 373(3):285-90. PubMed ID: 7589484
[TBL] [Abstract][Full Text] [Related]
10. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance.
Chen G; Waxman DJ
J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.
Schnur RC; Corman ML; Gallaschun RJ; Cooper BA; Dee MF; Doty JL; Muzzi ML; Moyer JD; DiOrio CI; Barbacci EG
J Med Chem; 1995 Sep; 38(19):3806-12. PubMed ID: 7562911
[TBL] [Abstract][Full Text] [Related]
12. Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase.
Brunton VG; Steele G; Lewis AD; Workman P
Cancer Chemother Pharmacol; 1998; 41(5):417-22. PubMed ID: 9523739
[TBL] [Abstract][Full Text] [Related]
13. Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2/neu activation, receptor expression and proliferation of Her-2-positive malignant cell lines.
Hartmann F; Horak EM; Cho C; Lupu R; Bolen JB; Stetler-Stevenson MA; Pfreundschuh M; Waldmann TA; Horak ID
Int J Cancer; 1997 Jan; 70(2):221-9. PubMed ID: 9009164
[TBL] [Abstract][Full Text] [Related]
14. Activity of N-benzyl-adriamycin-14-valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines.
Harstrick A; Vanhoefer U; Schleucher N; Schroeder J; Baumgart J; Scheulen ME; Wilke H; Seeber S
Anticancer Drugs; 1995 Oct; 6(5):681-5. PubMed ID: 8845478
[TBL] [Abstract][Full Text] [Related]
15. Insights into the biosynthesis of the benzoquinone ansamycins geldanamycin and herbimycin, obtained by gene sequencing and disruption.
Rascher A; Hu Z; Buchanan GO; Reid R; Hutchinson CR
Appl Environ Microbiol; 2005 Aug; 71(8):4862-71. PubMed ID: 16085885
[TBL] [Abstract][Full Text] [Related]
16. Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-glycoprotein or MRP overexpression.
Lee JS; Scala S; Matsumoto Y; Dickstein B; Robey R; Zhan Z; Altenberg G; Bates SE
J Cell Biochem; 1997 Jun; 65(4):513-26. PubMed ID: 9178101
[TBL] [Abstract][Full Text] [Related]
17. The multidrug resistance of tumour cells was reversed by tetrandrine in vitro and in xenografts derived from human breast adenocarcinoma MCF-7/adr cells.
Fu LW; Zhang YM; Liang YJ; Yang XP; Pan QC
Eur J Cancer; 2002 Feb; 38(3):418-26. PubMed ID: 11818209
[TBL] [Abstract][Full Text] [Related]
18. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein.
Goulding CW; Giuliano AE; Cabot MC
Cancer Lett; 2000 Feb; 149(1-2):143-51. PubMed ID: 10737718
[TBL] [Abstract][Full Text] [Related]
19. DNA damage induced by NADPH cytochrome P450 reductase-activated idarubicin in sensitive and multidrug resistant MCF7 breast cancer cells.
Żwierełło W; Maruszewska A; Nowak R; Kostrzewa-Nowak D; Tarasiuk J
Pharmacol Rep; 2017 Feb; 69(1):185-195. PubMed ID: 27940401
[TBL] [Abstract][Full Text] [Related]
20. Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.
Uchiyama-Kokubu N; Watanabe T; Cohen D
Jpn J Cancer Res; 2001 Oct; 92(10):1116-26. PubMed ID: 11676863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
